IGC Pharma reports Q2 2026 results; CALMA enrollment nears closure
IGC Pharma reports Q2 2026 results and says its CALMA Alzheimer’s trial moves within six randomizations of enrollment closure.
Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
1 result loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
IGC Pharma reports Q2 2026 results and says its CALMA Alzheimer’s trial moves within six randomizations of enrollment closure.